Economic assessment of eltrombopag in the treatment of thrombocytopenia

Federica Romano, Matteo Ruggeri, Silvia Coretti, Edoardo Giovanni Giannini, Dario Sacchini, Brigida Eleonora Annichiarico, Marco Marchetti, Francesco Rodeghiero, Dario Lidonnici

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. Methods: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. Results: Base case results demonstrate that scenario 1 is associated with a cost per QALY of e30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of e32,752.44 per QALY when scenario 1 is compared with scenario 3. Conclusion: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.

Original languageEnglish
Pages (from-to)713-720
Number of pages8
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume15
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

Thrombocytopenia
Economics
Quality-Adjusted Life Years
Hepacivirus
Cost-Benefit Analysis
Antiviral Agents
Therapeutics
Costs and Cost Analysis
Disease Progression
eltrombopag
Liver Diseases
Clinical Trials

Keywords

  • Cost-effectiveness
  • Markov model
  • Revolade
  • Sensitivity analysis
  • Thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy

Cite this

Economic assessment of eltrombopag in the treatment of thrombocytopenia. / Romano, Federica; Ruggeri, Matteo; Coretti, Silvia; Giannini, Edoardo Giovanni; Sacchini, Dario; Annichiarico, Brigida Eleonora; Marchetti, Marco; Rodeghiero, Francesco; Lidonnici, Dario.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, No. 4, 2015, p. 713-720.

Research output: Contribution to journalArticle

Romano, F, Ruggeri, M, Coretti, S, Giannini, EG, Sacchini, D, Annichiarico, BE, Marchetti, M, Rodeghiero, F & Lidonnici, D 2015, 'Economic assessment of eltrombopag in the treatment of thrombocytopenia', Expert Review of Pharmacoeconomics and Outcomes Research, vol. 15, no. 4, pp. 713-720. https://doi.org/10.1586/14737167.2015.1028373
Romano, Federica ; Ruggeri, Matteo ; Coretti, Silvia ; Giannini, Edoardo Giovanni ; Sacchini, Dario ; Annichiarico, Brigida Eleonora ; Marchetti, Marco ; Rodeghiero, Francesco ; Lidonnici, Dario. / Economic assessment of eltrombopag in the treatment of thrombocytopenia. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2015 ; Vol. 15, No. 4. pp. 713-720.
@article{478a0ba0ce504ae19997aa404641884c,
title = "Economic assessment of eltrombopag in the treatment of thrombocytopenia",
abstract = "Objective: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. Methods: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. Results: Base case results demonstrate that scenario 1 is associated with a cost per QALY of e30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of e32,752.44 per QALY when scenario 1 is compared with scenario 3. Conclusion: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.",
keywords = "Cost-effectiveness, Markov model, Revolade, Sensitivity analysis, Thrombocytopenia",
author = "Federica Romano and Matteo Ruggeri and Silvia Coretti and Giannini, {Edoardo Giovanni} and Dario Sacchini and Annichiarico, {Brigida Eleonora} and Marco Marchetti and Francesco Rodeghiero and Dario Lidonnici",
year = "2015",
doi = "10.1586/14737167.2015.1028373",
language = "English",
volume = "15",
pages = "713--720",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Economic assessment of eltrombopag in the treatment of thrombocytopenia

AU - Romano, Federica

AU - Ruggeri, Matteo

AU - Coretti, Silvia

AU - Giannini, Edoardo Giovanni

AU - Sacchini, Dario

AU - Annichiarico, Brigida Eleonora

AU - Marchetti, Marco

AU - Rodeghiero, Francesco

AU - Lidonnici, Dario

PY - 2015

Y1 - 2015

N2 - Objective: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. Methods: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. Results: Base case results demonstrate that scenario 1 is associated with a cost per QALY of e30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of e32,752.44 per QALY when scenario 1 is compared with scenario 3. Conclusion: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.

AB - Objective: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. Methods: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. Results: Base case results demonstrate that scenario 1 is associated with a cost per QALY of e30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of e32,752.44 per QALY when scenario 1 is compared with scenario 3. Conclusion: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.

KW - Cost-effectiveness

KW - Markov model

KW - Revolade

KW - Sensitivity analysis

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84945948851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945948851&partnerID=8YFLogxK

U2 - 10.1586/14737167.2015.1028373

DO - 10.1586/14737167.2015.1028373

M3 - Article

C2 - 26176754

AN - SCOPUS:84945948851

VL - 15

SP - 713

EP - 720

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 4

ER -